We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Tuesday, February 18, 2020, highlighting Roche’s early drug development with a focus on Genentech Research and Early Development (gRED).

We would like to invite all interested parties to dial in as outlined below:

Tuesday, February 18, 2020

15:30 – 17:00 CET/ 14:30 – 16:00 GMT
9:30 am – 11:00 am EST / 6:30 am – 8:00 am PST

Video webcast and conference call will start with presentations by senior researchers followed by a Q&A session (live access to the speakers).

Agenda:

Welcome
Karl Mahler, Head of Investor Relations and Roche Group Planning

Overview and Introduction to Genentech (gRED)
Michael Varney, Head of Genentech Research and Early Development

Non-Oncology Pipeline Overview
Andy Chan, Senior Vice President, Research Biology for gRED

Oncology Pipeline Overview
Stuart Lutzker, Vice President, Oncology Research and ad interim Head of Early Clinical Development for gRED

Cancer Immunotherapy
Ira Mellman, Vice President, Cancer Immunology and Immunology for gRED

Access to Video Webcast

Please access by clicking on > ir.roche.com

Access to Conference Call (pre-registration required)
You will receive phone numbers, passcode and your personal PIN to direct access the conference call by pre-registering here.
Should you have any issues with the registration, please dial the following numbers on the day of the conference call 10-15 minutes prior to conference start:

+41 (0) 58 310 50 00 (Europe & RoW)
+44 (0) 207 107 06 13 (UK)
+1 (1) 631 570 5613 (USA)

A replay of the webcast will be available via > ir.roche.com

Attachment

• 20200211_IR_gRED_Reminder_en